((自动化翻译由路透提供，请见免责声明 ))
11月1日 - ** 药物开发商莱克西康制药公司 股价盘前下跌约35.9%，至1.25美元
** 周四晚些时候，美国食品和药物管理局（FDA）顾问投票反对 (link) 推荐 Lexicon 的胰岛素治疗附加疗法用于控制 1 型糖尿病和慢性肾病成人患者的血糖水平。
** 专家小组以11:3的票数否决了索他利氟嗪（sotagliflozin）这种药物。
** 专家小组成员表示，他们对 缺乏临床数据感到 "失望"，因为可能受益最大的亚组患者没有得到前瞻性研究。
** 截至上一交易日收盘，股价累计上涨 27.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.